New Fortress Energy
NFE
DexCom
DXCM
Workday
WDAY
4
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
5
Ermenegildo Zegna NV
ZGN
US Stock MarketDetailed Quotes
CMPX Compass Therapeutics
- 2.125
- +0.055+2.66%
Trading Apr 24 15:16 ET
293.85MMarket Cap-5.90P/E (TTM)
2.130High1.970Low419.21KVolume2.080Open2.070Pre Close857.16KTurnover0.46%Turnover RatioLossP/E (Static)138.28MShares4.08052wk High2.35P/B192.80MFloat Cap0.76552wk Low--Dividend TTM90.73MShs Float8.800Historical High--Div YieldTTM7.73%Amplitude0.765Historical Low2.044Avg Price1Lot Size
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Compass Therapeutics Stock Forum
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
Monday, 21st April at 8:00 am
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored...
$Cloudastructure (CSAI.US)$ 107% RUNNER
$American Rebel (AREB.US)$ 88%
$Compass Therapeutics (CMPX.US)$ 66.54%
$Digital Ally (DGLY.US)$ 80.9%
$Microvast (MVST.US)$ 29.60%
$Newsmax (NMAX.US)$ 166% RUNNER
$Sonim Technologies (SONM.US)$ 52.22%
why decreasing ???
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tuesday, 1st April at 7:00 am
• Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting.
• The difference in ORR be...
Compass Therapeutics Announced Statistically Significant Top-line Data On The Primary Efficacy Endpoint For COMPANION-002, The Company's Ongoing Phase 2/3 Trial Of Tovecimig (Formerly CTX-009) In Combination With Paclitaxel In Patients With Advanced...
https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/f8k_040125.htm
Hosting webcast today - clinical data- companion-002
Cash - 127m runway into 2027
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
No comment yet